Brokerages forecast that Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will announce sales of $25.07 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Adamas Pharmaceuticals’ earnings. The highest sales estimate is $26.50 million and the lowest is $23.25 million. Adamas Pharmaceuticals posted sales of $20.18 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 24.2%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 4th.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year sales of $94.43 million for the current financial year, with estimates ranging from $90.28 million to $98.60 million. For the next year, analysts expect that the firm will report sales of $126.17 million, with estimates ranging from $112.10 million to $144.03 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Sunday, August 8th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.02.
Shares of Adamas Pharmaceuticals stock opened at $4.55 on Wednesday. The company has a current ratio of 5.30, a quick ratio of 4.94 and a debt-to-equity ratio of 21.25. The company’s fifty day simple moving average is $4.80 and its two-hundred day simple moving average is $5.05. The company has a market cap of $207.46 million, a P/E ratio of -2.69 and a beta of 2.69. Adamas Pharmaceuticals has a 12-month low of $2.96 and a 12-month high of $9.15.
In related news, insider Vijay Shreedhar sold 6,200 shares of the company’s stock in a transaction dated Monday, June 21st. The shares were sold at an average price of $5.16, for a total value of $31,992.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 18.90% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. The PNC Financial Services Group Inc. boosted its stake in Adamas Pharmaceuticals by 42.9% in the 1st quarter. The PNC Financial Services Group Inc. now owns 10,000 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 3,000 shares in the last quarter. HighTower Advisors LLC bought a new position in Adamas Pharmaceuticals in the 2nd quarter worth about $66,000. Cubist Systematic Strategies LLC bought a new position in Adamas Pharmaceuticals in the 2nd quarter worth about $76,000. Walleye Capital LLC bought a new position in Adamas Pharmaceuticals during the 1st quarter valued at about $80,000. Finally, XTX Topco Ltd bought a new position in Adamas Pharmaceuticals during the 2nd quarter valued at about $86,000. Institutional investors own 71.69% of the company’s stock.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.
Read More: What is a Reverse Stock Split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.